PATENT CLAIM ANALYSIS

Application Number: 15924511
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "186100"]

Abstract:
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

Claim (Index 20):
A method for producing the N-terminally truncated HPV11 L1 protein according to  claim 14 , comprising:\n a) expressing a HPV L1 gene encoding the N-terminally truncated HPV L1 protein in an  E. coli  expression system; b) disrupting the  E. coli , which has expressed the N-terminally truncated HPV L1 protein, in a solution at a salt concentration of from 100 mM to 600 mM, and isolating the supernatant; c) decreasing the salt concentration of the supernatant of b) to from 100 mM to 0, inclusive, by using water or a low salt solution, and collecting a precipitate; and d) redissolving the precipitation of c) in a solution at a salt concentration of from 150 mM to 2500 mM, adding a reductant to it, and then isolating the resultant solution, wherein the solution contains the N-terminally truncated HPV L1 protein with a purity of at least 50%.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 90.0
- Lexical Diversity: 1.48387
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15350264', '12601972', '14248063', '12601983', '12598187']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8485036130784418
- 35 USC 102 Novelty (BERT): 0.7147470495349885
- Combined Prediction Score: 0.8351279567240965
- Mean Citation Score: 748.287266
- Max Citation Score: 797.6519
- Similarity Product: 768.6564833021878

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test